Marketresearchnews

Wednesday, 7 April 2021

Menopause Treatment Market Growth Analysis, Industry Trends, And Forecast By 2027

Market Highlights

Global Menopause Treatment Market is expected to have a market value of USD 15,456.3 Million by 2027. Menopause causes uncomfortable symptoms, such as hot flashes, vaginal dryness, and weight gain and menopause treatments such as hormonal and non-hormonal treatments help to relieve these symptoms. Over the years, major market players in the menopause treatment are focusing on various growth strategies such as product launches, product advancements and expansions to cater to the growing needs for patients seeking treatment for menopause symptoms. For instance, in April 2019, Otsuka Pharmaceutical launched EQUELLE, a non-prescription, non-hormonal supplement to alleviate the frequency of hot flashes and muscle aches associated with menopause in the US. Such strategies push the demand for branded as well as generic menopausal drugs, thus promising huge growth for the industry.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4579

Segment Analysis

The global menopause treatment market is segmented based on treatment and distribution channel.

The global menopause treatment market based on the treatment has been segmented into hormonal treatment and non-hormonal treatment. The hormonal treatment segment is further segmented into estrogen, progesterone, and combination. The non-hormonal treatment is further segmented into anti-depressants and others.

Based on distribution channel, the menopause treatment market is segmented into hospital pharmacies, retail pharmacies, and online stores.

Regional Analysis

The global menopause treatment market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.

The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas led the market and accounted for the largest share in 2019 owing to the increasing product approvals and high uptake of new technology. For instance, in July 2017, AMAG Pharmaceuticals, Inc. (US) launched Intrarosa (prasterone) for the treatment of moderate to severe dyspareunia a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Thus, such strategies employed by major players aid in the increased growth rate for the Americas menopause treatment industry.

The European menopause treatment market has been further segmented into Western Europe and Eastern Europe. The Western Europe menopause treatment market has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. Europe follows the Americas in the global menopause treatment market. The increasing inclination of companies towards female technology (femtech) is boosting the growth of the menopause treatment market in European countries. Many digital health start-ups have identified this opportunity and are offering B2C digital health tools, such as mobile apps, to guide menopausal women through this phase with lifestyle intervention tips and online telehealth consultations. As a result, the region is expected to show significant growth in the menopause treatment market.

The menopause treatment market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the rest of Asia-Pacific. Asia-Pacific is expected to register the highest growth rate over the forecast period from 2020 to 2027. This is owing to the growing penetration of the women’s health sector, increasing awareness about the betterment of the women’s health, and the growing number of educational campaigns related to the benefits of hormone replacement therapy in China, Japan, India, and Australia.

The Middle East & Africa menopause treatment market is segmented Saudi Arabia, the United Arab Emirates (UAE), Oman, Kuwait, Qatar, and the rest of the Middle East & Africa. The negative connotation of menopause has resulted in a negative attitude towards menopause in premenopausal women. However, with the increasing awareness created by private companies, the scenario is expected to change in the next ten years.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Menopause Treatment Market— Novo Nordisk A/S (Denmark), Pfizer Inc. (US), Allergan (Ireland), Eli Lily and Company (US), Emcure Pharmaceuticals Ltd (India), Novartis AG (Switzerland), Cipla Inc. (India), Teva Pharmaceuticals (Israel), Merck & Co., Inc. (US), Abbott Laboratories (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/menopause-treatment-market-4579

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Nebulizers Market 2020 Global Trend, Segmentation And Opportunities, Forecast 2027

Global Nebulizers Market is expected to hold a value of USD 1,629.7 Million by 2027 and is expected to register a growth of 7.32% from 2020 to 2027.

Nebulizers Market Synopsis

Nebulizers are a device that has the capability of changing a medication from a liquid to a mist so that it can be inhaled into the lungs. High demand for respiratory devices, including nebulizers, due to the outbreak of COVID-19 globally, growing need for rescue medication, increasing prevalence of respiratory diseases, and rising demand for home healthcare devices are the key factors that are expected to drive the market growth. Moreover, the growing geriatric population, increasing consumption of alcohol, tobacco, cigarettes, and other such products may lead to respiratory diseases, and the rising number of initiatives taken by the government as well as the private organizations are also expected to boost the market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/9586

The growth of the global nebulizers market can be contributed to the growing need for rescue medication, high demand for respiratory devices, including nebulizers, due to outbreak of COVID-19 globally, and increasing prevalence of chronic respiratory diseases. According to a press release from Icon Plc in April 2020, the demand for respiratory devices has enormously increased, due to the rising cases of COVID-19.

Furthermore, the growing demand for home healthcare devices, rising geriatric population, increasing consumption of alcohol, tobacco, cigarettes, and other such products that might lead to respiratory diseases, are also expected to fuel the market growth during the forecast period.

However, the loss of drug during nebulization procedures, availability of various substitutes for nebulizers, and side effects of nebulizer solutions are expected to restrain the growth of the global nebulizers market.

Several market players such as OMRON Healthcare, Koninklijke Philips N.V., and B. Braun Melsungen AG, among others currently dominate the global nebulizers market. The key players are involved in awareness campaigns, product approvals, mergers, and strategic collaborations to strengthen their market positions. For instance, in April 2020, B. Braun Melsungen AG received the Food and Drugs Administration (FDA) emergency use authorization for using its infusion pumps with nebulizers to treat COVID-19 patients.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas region held the largest market in 2019, owing to the rising demand for respiratory diseases in the region. The nebulizers market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European nebulizers market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The nebulizers market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing incidence rate of respiratory diseases, the market in Asia-Pacific is expected to be the fastest-growing. The nebulizers market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global Nebulizers Market has been Segmented Based on the Type, Usage, Portability, and End User.

Based on the Type, the global nebulizers market has been segmented into mesh, jet, and ultrasonic. The mesh segment is further divided into active and passive. The jet segment is expected to hold the largest market share owing to its low cost as compared to other types of nebulizers.

On the basis of usage, the market has been segmented into reusable and disposable. The disposable nebulizers are expected to hold a major market share owing to their growing popularity amongst the users.

Based on the portability, the market has been segmented into tabletop and portable. The portable nebulizers market is expected to grow at the fastest CAGR owing to its ease and convenience of use.

The market based on end-user has been segmented into hospitals & clinics, home care, and others. The hospitals and clinics segment is expected to hold the largest market share owing to the larger patient footfall in hospitals.

Key Players

Some of the key players in the global nebulizers market are OMRON Healthcare (Japan), Koninklijke Philips N.V. (Netherlands), PARI (US), Vectura Group plc (UK), Rossmax International Ltd (Taiwan), Briggs Healthcare (US), GF Health Products, Inc. (US), Beurer GmBH (Germany), Agilent Technologies, Inc. (US), Drive DeVilbiss Healthcare (US), Invacare Corporation (US), and B. Braun Melsungen AG (Germany).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nebulizers-market-9586

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Electronic Trial Master File (eTMF) Systems Market 2020 Insights Business Opportunities, Current Trends And Restraints Forecast 2027

Global eTMF Systems Market is expected to reach a value of USD 1825 Million by 2025, at a CAGR of 13.11% during the assessment period of 2019 to 2025.

The pharmaceutical, as well as the biotechnology companies, face a major challenge to maintain a central repository for the storage of clinical trial documents for use in regulatory submissions. Therefore, there emerges a need to store all the data produced by these companies effectively. As a result, software companies have developed electronic trial master file systems that aid these companies as well as the contract research organizations in systemized storage of files. Moreover, in comparison to the traditional storage systems, electronic trial master file systems facilitate content classification and easier interoperability in clinical trial operations. Therefore, the major companies are continuously involved in new product launches to gain a competitive edge over the other players.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8772

The growth of the global eTMF systems market is fueled by several factors such as rising activities in terms of acquisitions, new solution and service deployments, and collaborations by key players operating in the market, coupled with the increasing number of clinical trial studies. For instance, in October 2019, SureClinical Inc. launched a transparent eTMF pricing policy. To provide value to the prospective users, the company has posted its prices and terms online to battle price discrimination in this industry. However, budget constraints of the small and medium-sized enterprises, along with the dearth of skilled professionals for operating the electronic systems, can hinder the preference of such solutions. As a result, such elements can hamper the growth of the market during the forecast period.

Several market players currently dominate the global eTMF systems market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in June 2018, Phlexglobal, a UK-based specialist provider of TMF and eTMF management solutions, is adopting Version 1 of the eTMF Exchange Mechanism Standard (eTMF-EMS) of the TMF Reference Model (TMF-RM) into PhlexEview, the company’s eTMF technology. Such strategies push the growth of the eTMF systems market.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held the maximum share in the base year 2018, owing to the presence of established key players in countries such as the US and Canada. The eTMF systems market in the Americas has been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European eTMF systems market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The eTMF systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The eTMF systems market in this region is anticipated to be the fastest-growing during the assessment period due to the increased adoption rate of eTMF software and services in the Asian countries. The eTMF systems market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global eTMF Systems Market has been segmented based on Component, Deployment Mode, and End User.

The global eTMF systems market has been segmented, based on the component, into software and services. The software segment is expected to hold the majority share of the market owing to the increasing number of solution launches by the prominent players in recent years. The services segment is expected to be the fastest-growing due to the increasing uptake of eTMF services by pharmaceutical and life science companies.

The global eTMF systems market, based on deployment model, has been segmented into cloud/web-based, and on-premise. The cloud/web-based segment holds the maximum share owing to the technological advancements in cloud-based solutions in recent years.

The end-users of the market are pharmaceutical and biotechnology companies, contract research organizations, and others. The increasing number of clinical trials conducted by pharma firms is leading to the market size of the pharmaceutical and biotechnology companies’ segment.

Key Players

Some of the Key Players in the Global eTMF Systems Market are Aurea, Inc. (US), Covance Inc. (US), ePharmaSolutions (US), MasterControl, Inc. (US), Oracle (US), Phlexglobal (UK), SureClinical Inc. (US), TransPerfect (US), Veeva Systems (US), and Wingspan (IQVIA) (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/etmf-systems-market-8772

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Avian Influenza Vaccine Market Overview With Detailed Analysis, Competitive Landscape, Forecast To 2027

Global Avian Influenza Vaccine Market is expected to register a CAGR of 7.25% to reach USD 735.22 Million by 2025. Avian influenza, also known as bird flu, is a viral infection that spreads from bird to bird and can infect other animals or humans also. There are different strains of avian influenza, causing the infection, but H5V1 is the most common virus strain affecting poultry animals.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8769

Market Dynamics

The increasing strategic agreements are expected to drive market growth during the study period. For instance, in February 2018, the NC State College of Veterinary Medicine and Ceva Santé Animale, an animal health company, based in France, collaborated on a distance learning project providing certification in poultry health management for veterinarians in Latin America. Moreover, the increasing public & private initiatives by the government as well as non-government organizations for research & development are also anticipated to drive the market growth.

Segmentation

The Global Avian Influenza Vaccine Market has been segmented by strain and application. The market, based on strain, has been bifurcated into H5, H7, and H9. Based on application, the avian influenza vaccine market has been chicken, turkey, and goose & duck.

Regional Analysis

The Global Avian Influenza Vaccine Market, based on region, has been divided into the APAC & Middle East, Europe, Americas, and Africa.

The APAC & Middle East is likely to dominate the global avian influenza vaccine market. This can be attributed to the increasing production of poultry birds and the rise in avian influenza outbreaks in the region. According to a recent report from the Foreign Agricultural Service/USDA, China recorded 13,800 thousand metric tons of chicken meat production in 2019. Furthermore, various government initiatives for rapid and effective response efforts to emergent zoonotic influenza viruses are also expected to drive market growth.

The European market for the avian influenza vaccine is estimated to be the second-largest during the review period. The growing dependence on poultry as the key source of protein in the diet in this region is expected to boost the growth of the regional market. According to the European Commission, the European Union (EU) produced 15.2 million tons of poultry meat in 2018. Additionally, increasing the production of veterinary products and improved animal husbandry practices in Germany and Poland are further fueling market growth.

Americas is estimated to demonstrate significant market growth owing to the growing meat & poultry industry, the increasing expenditure on animal health, and the presence of a large number of veterinary hospitals in the region. According to the North American Meat Institute, the US exported 3.7 million metric tons (MT) of poultry and poultry variety meats in 2017. The value was estimated at USD 4.5 billion. Moreover, growing government support for creating awareness on avian influenza viruses and improving efficiency for the avian influenza vaccine is also positively affecting the market growth.

Key Players

The Prominent Players in the Global Avian Influenza Vaccine Market are Boehringer Ingelheim International GmbH (Germany), Guangdong Wenshi Dahuanong Biotechnology Co., Ltd (China), Ceva (US), Yebio Bioengineering Co., Ltd (China), Zoetis (US), FATRO S.P.A. (Italy), CAVAC (South Korea), Tianjin Ringpu Bio-Technology Co., Ltd (China), PT Japfa Comfeed Indonesia Tbk (Indonesia), Chengdu Tech-bank Biological Products Co., Ltd (China), Merck Animal Health (US), Medion (Indonesia), Avimex Animal Health (Mexico), JOVAC (Jordan), and QYH BIOTECH COMPANY LIMITED (China). Some of the key strategies followed by players operating in the global avian influenza vaccine market were collaborations, acquisition, product approval & launch, and expansion.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/avian-influenza-vaccine-market-8769

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Interventional Cardiology Market Growth Analysis, Industry Trends, And Forecast By 2027

Interventional Cardiology Market Forecast

Global Interventional Cardiology Market held a value of USD 15,130.75 Million in 2018 and is expected to register a CAGR of 7.25% during the assessment period of 2019 to 2025.

Interventional Cardiology Market Synopsis

Interventional cardiology deals with the catheter-based treatment of heart diseases. Scrutinizing all the global territories, it has been noticed that there is a huge rise in the number of cardiac diseases. This can be attributed to the change in lifestyle, leading to lifestyle diseases. Each year cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU).

In addition to that, the rise in the number of clinical trials of devices for use in interventional cardiology procedures is set to propel the growth of the market. For instance, in August 2018, B. Braun Melsungen AG announced that its drug-coated balloon ‘SeQuent Please’ for percutaneous transluminal coronary angioplasty showed positive results in the BASKET-SMALL 2 clinical trial. Moreover, the trend of bioresorbable stents going to contribute substantially to the growth of the market. For instance, in February 2019, Biotronik was granted approval from the FDA for its a drug-eluting stent system which is ultrathin and bioabsorbable for the treatment of patients with coronary artery disease.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8735

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held maximum share in the base year 2018, owing to the high incidence rates of cardiac disorders and strategic activities by major players in countries such as the US. The interventional cardiology market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European interventional cardiology market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The European market for interventional cardiology is expected to hold a substantial share owing to the increase in the number of cardiac disorder cases. For instance, in 2016, there were 66,076 deaths due to coronary heart diseases in the UK, which was the third-highest cause of death in that particular year. The interventional cardiology market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The interventional cardiology market in this region is anticipated to be the fastest-growing during the forecast period due to the increasing uptake and adoption rate of newer treatment options by patients as well as medical professionals. The increasing patient pool and mortality rate due to cardiac diseases in these countries also fuel the market growth. For instance, in 2017, ischemic heart disease was the second-highest cause for death in Japan. The interventional cardiology market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global Interventional Cardiology Market has been segmented based on Type, and End User.

The market, based on type, has been segmented into stents, percutaneous transluminal coronary angioplasty (PTCA) catheters, plaque modification devices, coronary guidewires, and accessories. The market, based on stents, has been further divided into drug-eluting stents, bare-metal stents, and bioresorbable vascular scaffolds. The stents segment held a major share in 2018 owing to the increased number of product launches by key players in the current years. This segment is also expected to be the fastest-growing segment during the forecast period due to the increasing prevalence of coronary artery disease, and continued innovations by players. The market, based on PTCA catheters, has been segmented into balloon catheters, and guiding catheters.

The Global Interventional Cardiology Market has been segmented, based on end-user, into hospitals, cardiac catheterization laboratories, ambulatory surgical centers, and others. In 2018, the hospital's segment held the majority share of the market owing to the increasing number of patient admissions due to coronary diseases. The cardiac catheterization laboratory segment is projected to be the fastest-growing segment owing to the increasing preference of cath labs by medical professionals.

Key Players

Some of the Key Players in the Global Interventional Cardiology Market are ABIOMED (US), Abbott (US), ACIST Medical Systems, Inc. (the US), B. Braun Melsungen AG (Germany), BD (US), Biosense Webster, Inc (US), Biotronik SE & Co. KG (Germany), Boston Scientific Corporation (US), Cardinal Health (US), Cook Medical (US), Edwards Lifesciences Corporation (US), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Life Vascular Devices Biotech S.L. (Spain), Medtronic (Ireland), Merit Medical Systems, Inc (US), Terumo Corporation (Japan), and W. L. Gore & Associates, Inc. (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/interventional-cardiology-market-8735

Influenza Vaccines Market 2020 Global Dynamics, Trends, Opportunities, Drivers, Challenges And Influence Factors Shared In A Latest Report

The global influenza vaccines market is predicted to reach USD 7,828.3 Million by 2025 to register a CAGR of 6.53%. The influenza virus is a very common and deadly viral infection with the potential of infecting the respiratory system of human beings. The influenza virus is a contagious respiratory illness that affects the lungs, nose, and throat. People who have week immunity systems or who have chronic diseases are at high risks. It is a viral disease that spreads from one person to another in oozing of the lungs and nose.

Vaccines work with the body’s natural defense to fabricate protection by reducing the risks of getting infected. A vaccine helps to produce the antibodies in the immunity system to fight the diseases. One or more doses of the vaccine typically protect against the diseases for a few years, decades, or maybe even for a lifetime. There is mostly two influenza vaccine type which is widely available in the market, these are inactivated influenza vaccine (IIV) and live attenuated influenza vaccines (LAIV). These vaccines are made to protect against three seasonal viruses. Influenza viruses are a threat to the human population, under the major public health estimation; vaccinations are the ultimate prevention from the disease.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1621

Global Influenza Vaccination Market - Competitive Analysis

Abbott (U.S.), AstraZeneca (Europe), BioCryst Pharmaceuticals, Inc. (U.S.), Novartis AG (Europe), DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific), GlaxoSmithKline plc. (Europe). Hualan Biological Engineering Inc (Asia Pacific), Mitsubishi Tanabe Pharma Corporation (Asia Pacific), F. Hoffmann-La Roche Ltd (Europe), Sanofi (Europe), Paxvax Corporation (U.S.) are some of the prominent players at the forefront of competition in the Global Influenza Vaccination Market and are profiled in MRFR Analysis.

GSK plc. is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. As one of the few healthcare companies researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria, the company has developed some of the leading global medicines in these fields. GSK’s product portfolio also includes a range of consumer brands, many of which are household names around the world, including Sensodyne, Aquafresh, Horlicks, Panadol and Tums.

GSK plc. is headquartered ate Middlesex, United Kingdom. Geographically, the company operates in the regions like North America, South and Central America, Europe, Middle East, Asia, Africa and Australia. The company has a headcount of more than 10,000 employees all across world.

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial.

The company is also a P5 member (Pox-Protein-Public Private Partnership) for the development of the HIV vaccine candidate RV 144 that is in the III phase

Sanofi is headquartered in Paris, France. Geographically, the company operates in the regions like North America, South America, Europe and Asia-Pacific, Africa in more than 100 countries with the headcount of more than 10,000 employees.

Incorporated in 2007 and headquartered at California, United State; PaxVax is a biotechnology company that is dedicated in develops, manufactures and commercializes innovative specialty vaccines against infectious diseases; cholera (Vaxchora) & typhoid fever (Vivotif) and vaccines at various stages of research and clinical advancement for HIV, adenovirus, anthrax, hepatitis A, and zika. The company has its research and development centers in various countries like San Diego, California and Bern, Switzerland and other operations in Bermuda and Europe.

The company focuses mainly on delivering its HIV vaccine in various regions all around the world. The company has raised around $200 million from its investors including Cerberus Capital Management, Ignition Growth, Ignition Ventures and the Wellcome Trust. The company also has collaborations with various organizations for its research & development from the U.S. National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation.

The company is specialized in various Viral Vaccines, Cholera, HIV, Adenovirus, Influenza, Vivotif oral typhoid vaccine.

Geographically, the company operates in various regions like San Diego, California Bern, Switzerland, United States, Europe and Bermudathe. As of now the company has a headcount of around 200 employees operating from various regions

Global Influenza Vaccination Market - Regional Analysis

America dominates the global influenza vaccination market. Increasing prevalence of the influenza and high per capita healthcare expenditure are the major driver for the American influenza vaccination market. Moreover, the presence of developed economies like the U.S. and Canada and growing geriatric population within the regional boundaries of the Americas fuels the market growth. Europe holds the second market for influenza vaccination owing to the availability of funds for research and huge patient population. Moreover, global players like F. Hoffmann-La Roche Ltd and Novartis AG are present within the region which fuels the market growth. Asia Pacific is the fastest growing region for the market. Presence of developing economies like India and China and favourable government policies along with the growing geriatric population boosts the regional market growth. The Middle East & Africa has the least share in the global influenza vaccination market. Presence of the poor economies in the African region restrains the market growth during the forecast period. Majority of the market of the Middle & Africa region is held by the Middle East region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/influenza-vaccination-market-1621

Global Primary Cells Market 2020 Insights Business Opportunities, Current Trends And Restraints Forecast 2027

Primary Cells Market is expected to register a CAGR of 8.13% to reach USD 1,233.67 Million till 2025.

Primary human cells are isolated directly from normal human tissue or blood cells via the enzymatic or mechanical method. Primary cells retain their fundamental cellular functions. Hence, their use in cell-based research programs is increasing significantly.

Key factors that drive the primary cells market are the rapid growth in the biotechnology and biopharmaceutical industries, growing cancer research, rising adoption of primary cells over cell lines, increasing demand for monoclonal antibodies, and increasing healthcare expenditure are anticipated to drive the growth of the market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5356

However, factors such as the high cost of advanced primary cells, and the risk of contamination may hamper the growth of the market. The increasing preference of primary cells in research and development to develop new drug acts as opportunities for the growth of the primary cells market.

Segment Analysis

The Global Primary Cells Market is segmented into Source, Type, and End User. By source, the market has been segmented into hematopoietic cells, skin cells, gastrointestinal cells, liver cells, lung cells, and skeletal and muscle cells.

Based on type, the market has been segmented into human primary cells and animal primary cells. On the basis of end user, the market has been segmented into pharmaceutical and biotechnology companies and research institutes.

Regional Analysis

The Global Primary Cells Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to hold the largest share of the global primary cells market. This is owing to the increasing prevalence of cancer and growing government funding in research. Also, the key players in the market are engaged in new launches and strategic collaborations to hold their market position. For instance, in January 2017, STEMCELL Technologies Inc. entered into a license agreement with Cincinnati Children’s Hospital Medical Center, to commercialize the center’s technology for producing gastrointestinal organoids from pluripotent stem cells (PSCs). Thus, all these factors are driving the primary cells market.

The European market holds the second-largest position in the global primary cells market. Factors attributing to the growth of the market include the rising prevalence of lifestyle-associated conditions, and the presence of developed economies such as Germany, the UK, and France boosts the market growth.

Asia-Pacific is estimated to be the fastest-growing region owing to the rising prevalence of chronic and acute diseases such as HIV, cancer, and diabetes, and the development of new infrastructure to support the healthcare industry are expected to drive the market growth.

The primary cells market in the Middle East & Africa is expected to grow at a significant rate owing to the implementation of a new business strategy such as a growing distribution channel, product launch in the untapped market by the healthcare companies increases the market growth in this region.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Primary Cells Market—Thermo Fisher Scientific Inc. (US), AllCells (US), American Type Culture Collection (ATCC) (Virginia), Axol Bioscience Ltd (UK), Cell Biologics, Inc. (Chicago), Lonza Group, AG (Switzerland), Merck KGaA (Germany), PromoCell (UK), STEMCELL Technologies Inc. (Canada), ZenBio, Inc. (Research Triangle Park, NC), and among others.

Key Findings of the Study

The Global Primary Cells Market was valued at USD 722.61 Million in 2018, is estimated to grow at USD 1,233.67 Million by 2025 at a CAGR of 8.13% during the assessment period

Asia-Pacific accounted for the largest share of the global market due to the increasing per capita health spending, growing geriatric population base, and developing countries enhance the market growth

Based on source, the hematopoietic cells segment accounted for the largest market share in 2018

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/primary-cells-market-6296